{"id":"carbamazepine-oxcarbazepine","safety":{"commonSideEffects":[{"rate":"26–49%","effect":"Dizziness"},{"rate":"20–36%","effect":"Somnolence"},{"rate":"13–32%","effect":"Headache"},{"rate":"5–31%","effect":"Ataxia"},{"rate":"14–40%","effect":"Diplopia"},{"rate":"7–29%","effect":"Nausea"},{"rate":"0.3–3%","effect":"Hyponatremia"},{"rate":"1–3%","effect":"Rash (including Stevens-Johnson syndrome, rare)"}]},"_chembl":{"chemblId":"CHEMBL1068","moleculeType":"Small molecule","molecularWeight":"252.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxcarbazepine is a keto-analogue of carbamazepine that stabilizes inactivated sodium channels, limiting repetitive neuronal firing. It also modulates high-voltage-activated calcium channels. These actions reduce the spread of seizure activity across neural networks, making it effective for seizure control.","oneSentence":"Oxcarbazepine blocks voltage-gated sodium channels to reduce neuronal excitability and prevent seizure propagation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:20.377Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures (monotherapy and adjunctive therapy)"},{"name":"Generalized tonic-clonic seizures (adjunctive therapy)"},{"name":"Bipolar disorder (off-label use)"}]},"trialDetails":[{"nctId":"NCT02219373","phase":"PHASE3","title":"Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study","status":"NOT_YET_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2026-06","conditions":"Pediatric Chronic Neuropathic Pain","enrollment":60},{"nctId":"NCT07252453","phase":"NA","title":"Comparison b/w Carbamazepine vs Oxcarbazepine in Treatment of Trigeminal Neuralgia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbasi Shaheed Hospital","startDate":"2025-05-20","conditions":"Trigeminal Neuralgia","enrollment":122},{"nctId":"NCT03196466","phase":"","title":"Population Pharmacokinetics of Antiepileptic in Pediatrics","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-19","conditions":"Epilepsy","enrollment":753},{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT05450978","phase":"","title":"Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding","status":"RECRUITING","sponsor":"University of Pittsburgh","startDate":"2022-07-20","conditions":"Epilepsy, Pregnancy Related","enrollment":60},{"nctId":"NCT01679002","phase":"PHASE1","title":"Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2003-10","conditions":"Epilepsy","enrollment":12},{"nctId":"NCT06849219","phase":"PHASE4","title":"Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2024-09-21","conditions":"Trigeminal Neuralgia","enrollment":122},{"nctId":"NCT00849797","phase":"PHASE1","title":"Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2005-07","conditions":"Healthy","enrollment":120},{"nctId":"NCT00850174","phase":"PHASE1","title":"Oxcarbazepine 600 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2005-04","conditions":"Healthy","enrollment":60},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT00154323","phase":"PHASE4","title":"The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-01","conditions":"Bipolar Disorder","enrollment":55},{"nctId":"NCT05697614","phase":"PHASE4","title":"The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children","status":"UNKNOWN","sponsor":"Dr Cipto Mangunkusumo General Hospital","startDate":"2023-03-01","conditions":"Drug Resistant Epilepsy","enrollment":100},{"nctId":"NCT05236166","phase":"NA","title":"Multicentre Study on Rapid Versus Slow Withdrawal of Antiepileptic Monotherapy","status":"COMPLETED","sponsor":"University Magna Graecia","startDate":"2017-04-26","conditions":"Epilepsy","enrollment":48},{"nctId":"NCT04996199","phase":"PHASE4","title":"Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical Trial","status":"UNKNOWN","sponsor":"Postgraduate Institute of Dental Sciences Rohtak","startDate":"2021-09-18","conditions":"Trigeminal Neuralgia","enrollment":132},{"nctId":"NCT00467753","phase":"NA","title":"Oxcarbazepine Versus Placebo in Childhood Autism","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2006-04","conditions":"Autism","enrollment":5},{"nctId":"NCT03490487","phase":"PHASE4","title":"Electroclinical Effect of Steroid in Patients With Benign Childhood Epilepsy With Centrotemporal Spikes","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-06-20","conditions":"Benign Childhood Epilepsy With Centrotemporal Spikes","enrollment":100},{"nctId":"NCT03695094","phase":"PHASE1","title":"A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2018-09-18","conditions":"Epilepsy","enrollment":31},{"nctId":"NCT04371575","phase":"","title":"Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients","status":"COMPLETED","sponsor":"Stine Maarbjerg, MD PhD","startDate":"2012-09-01","conditions":"Trigeminal Neuralgia, Multiple Sclerosis, Pain, Neuropathic","enrollment":60},{"nctId":"NCT02707965","phase":"PHASE1","title":"Characterization of Epilepsy Patients BEEP 2b","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2017-06-08","conditions":"Epilepsy","enrollment":21},{"nctId":"NCT01051193","phase":"PHASE2, PHASE3","title":"Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2010-01-05","conditions":"Partial Onset Seizures","enrollment":88},{"nctId":"NCT03374709","phase":"PHASE4","title":"Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2018-12-14","conditions":"Trigeminal Neuralgia","enrollment":""},{"nctId":"NCT02456896","phase":"PHASE4","title":"Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2015-06","conditions":"Bipolar Disorder","enrollment":50},{"nctId":"NCT00404248","phase":"PHASE1, PHASE2","title":"Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-01","conditions":"Brain and Central Nervous System Tumors","enrollment":35},{"nctId":"NCT02104661","phase":"PHASE2","title":"Protective Role of Oxcarbazepine in Multiple Sclerosis","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-10","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00616681","phase":"NA","title":"Bioequivalency Study of 600 mg Oxcarbazepine Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2004-06","conditions":"Seizures, Epilepsy","enrollment":28},{"nctId":"NCT01703468","phase":"PHASE1","title":"Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2009-09","conditions":"Seizures","enrollment":59},{"nctId":"NCT00618046","phase":"NA","title":"Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2004-11","conditions":"Seizures, Epilepsy","enrollment":48},{"nctId":"NCT01702623","phase":"PHASE1","title":"Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2009-09","conditions":"Seizures","enrollment":64},{"nctId":"NCT00616863","phase":"NA","title":"Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2004-07","conditions":"Epilepsy, Seizures","enrollment":28},{"nctId":"NCT02705768","phase":"PHASE4","title":"Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2016-04","conditions":"Seizures, Focal","enrollment":90},{"nctId":"NCT01891890","phase":"PHASE3","title":"Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)","status":"TERMINATED","sponsor":"Emory University","startDate":"2013-08","conditions":"Epilepsy, Partial, Epilepsy, Localization Related","enrollment":72},{"nctId":"NCT00918047","phase":"PHASE1","title":"Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2009-06","conditions":"Epilepsies, Partial","enrollment":18},{"nctId":"NCT00908349","phase":"PHASE3","title":"Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2009-06","conditions":"Partial Epilepsy","enrollment":214},{"nctId":"NCT00918424","phase":"","title":"Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects","status":"APPROVED_FOR_MARKETING","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2009-06","conditions":"Epilepsy","enrollment":""},{"nctId":"NCT00275912","phase":"PHASE4","title":"Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-09-11","conditions":"Epilepsy, Partial Seizures","enrollment":60},{"nctId":"NCT02078089","phase":"PHASE1","title":"Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain","status":"TERMINATED","sponsor":"Costantine Albany","startDate":"2014-03-06","conditions":"Cancer","enrollment":1},{"nctId":"NCT02556320","phase":"NA","title":"Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2013-05","conditions":"Epilepsy, Drug Hypersensitivity Syndrome","enrollment":30},{"nctId":"NCT01498822","phase":"PHASE4","title":"Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy","status":"COMPLETED","sponsor":"Korea UCB Co., Ltd.","startDate":"2011-06","conditions":"Epilepsy","enrollment":353},{"nctId":"NCT00260247","phase":"PHASE4","title":"Induction of Drug Metabolism: In Vivo Comparison of Carbamazepine and Oxcarbazepine.","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2005-04","conditions":"Metabolic Clearance Rate","enrollment":10},{"nctId":"NCT00068770","phase":"PHASE2","title":"Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2003-10","conditions":"Brain and Central Nervous System Tumors","enrollment":35},{"nctId":"NCT01893229","phase":"PHASE4","title":"Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania","status":"UNKNOWN","sponsor":"Guiyun Xu","startDate":"2013-09","conditions":"Bipolar Disorder","enrollment":120},{"nctId":"NCT01678976","phase":"PHASE1","title":"Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2002-03","conditions":"Epilepsy","enrollment":13},{"nctId":"NCT00900237","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2008-11","conditions":"Partial Epilepsy","enrollment":14},{"nctId":"NCT02180880","phase":"PHASE4","title":"Symptom Based Treatment of Neuropathic Pain","status":"COMPLETED","sponsor":"Ju Seok Ryu","startDate":"2012-11","conditions":"Neuralgia, Spinal Cord Injury","enrollment":63},{"nctId":"NCT01302275","phase":"PHASE4","title":"Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain","status":"COMPLETED","sponsor":"Søren H. Sindrup","startDate":"2011-02","conditions":"Polyneuropathy, Peripheral Nerve Injury, Postherpetic Neuralgia","enrollment":117},{"nctId":"NCT00772603","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2008-11","conditions":"Epilepsies, Partial","enrollment":366},{"nctId":"NCT00610571","phase":"PHASE1","title":"Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas","status":"COMPLETED","sponsor":"Katy Peters","startDate":"2004-04","conditions":"Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma","enrollment":62},{"nctId":"NCT00612651","phase":"PHASE1","title":"PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas","status":"COMPLETED","sponsor":"Duke University","startDate":"2005-10","conditions":"Gliosarcoma, Glioblastoma, Anaplastic Astrocytoma","enrollment":37},{"nctId":"NCT00734864","phase":"PHASE1","title":"Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma","status":"WITHDRAWN","sponsor":"Annick Desjardins","startDate":"2009-06","conditions":"Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma","enrollment":""},{"nctId":"NCT01390909","phase":"","title":"Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":"Epilepsy","enrollment":12386},{"nctId":"NCT00154362","phase":"PHASE4","title":"The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-04","conditions":"Conduct Disorder","enrollment":50},{"nctId":"NCT00050947","phase":"PHASE3","title":"Pediatric Epilepsy Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-07","conditions":"Epilepsy","enrollment":94},{"nctId":"NCT00050934","phase":"PHASE3","title":"Pediatric Epilepsy Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-06","conditions":"Epilepsy, Epilepsies, Partial","enrollment":132},{"nctId":"NCT00951847","phase":"NA","title":"Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5mL Under Fed Condition","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2006-10","conditions":"Healthy","enrollment":40},{"nctId":"NCT00951600","phase":"NA","title":"Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5 mL Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2006-09","conditions":"Healthy","enrollment":40},{"nctId":"NCT00552526","phase":"PHASE4","title":"Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2007-11","conditions":"Epilepsy, Mental Retardation","enrollment":60},{"nctId":"NCT00142025","phase":"PHASE4","title":"Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma","status":"COMPLETED","sponsor":"Centre of Chinese Medicine, Georgia","startDate":"2001-09","conditions":"Bronchial Asthma","enrollment":55},{"nctId":"NCT00637234","phase":"PHASE2, PHASE3","title":"Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2004-07","conditions":"Schizophrenia","enrollment":54},{"nctId":"NCT00275925","phase":"PHASE4","title":"Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial Seizures","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":"Epilepsy, Partial Seizures","enrollment":80},{"nctId":"NCT00145691","phase":"PHASE3","title":"The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD)","status":"COMPLETED","sponsor":"Sykehuset Innlandet HF","startDate":"2005-09","conditions":"Agitation Aggression in Dementia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"carbamazepine oxcarbazepine","genericName":"carbamazepine oxcarbazepine","companyName":"Odense University Hospital","companyId":"odense-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxcarbazepine blocks voltage-gated sodium channels to reduce neuronal excitability and prevent seizure propagation. Used for Partial-onset seizures (monotherapy and adjunctive therapy), Generalized tonic-clonic seizures (adjunctive therapy), Bipolar disorder (off-label use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}